Is 10X Genomics Inc (TXG) overvalued? · rev $610.8M
10X Genomics Inc (TXG) is a health information services company listed on NASDAQ.
This page asks whether 10X Genomics Inc (TXG) looks expensive on cached numbers — not a short thesis.
Latest reported TXG revenue for 2024-12-31 was $610.8M. Net income was -$182.6M. Revenue was down 1.3% from 2023-12-31 to 2024-12-31. TXG currently screens at market cap $4.08B.
TXG currently screens at market cap $4.08B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TXG 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TXG stock page for the full model, not this heading.
Not investment advice.